Artificial Intelligence in Drug Discovery and Development: Transforming Pharmaceutical Innovation
Clinical Snapshot
PICO Framework
| P — Population | Drug discovery and development processes across pharmaceutical industry |
| I — Intervention | Artificial intelligence applications (machine learning, deep learning, natural language processing) |
| C — Comparator | Traditional drug discovery methods |
| O — Outcomes | Efficiency, accuracy, speed, cost reduction, attrition rates in drug development pipeline |
Bottom Line
This narrative review examines AI applications in drug discovery but lacks the systematic methodology required for evidence-based practice recommendations. While the topic is highly relevant to modern pharmaceutical innovation, the absence of a comprehensive search strategy, quality assessment, and quantitative analysis significantly limits its clinical utility. The review identifies potential benefits of AI in target identification, lead optimization, and toxicity prediction, but provides insufficient evidence to support specific practice changes. Healthcare professionals should await more rigorous systematic reviews or primary research before implementing AI-driven approaches in drug discovery. The challenges highlighted regarding algorithmic transparency and regulatory acceptance remain valid concerns requiring further investigation.
Key Findings
Effect Size: Not quantified
Primary Outcome: AI applications improve efficiency and accuracy across drug discovery pipeline
Nnt Or Sensitivity: Claims of 'unprecedented speed and precision' but no specific metrics provided
Confidence Interval: Not provided
Clinical Application
Limited by lack of specific implementation guidance and evidence quality Relevant to Australian pharmaceutical research sector and TGA regulatory considerations, but no specific local context provided Pharmaceutical researchers and drug development professionals
Abstract
Drug discovery remains a lengthy, costly, and high-risk endeavor, often requiring over a decade from target identification to clinical translation. Artificial intelligence (AI) is reshaping this paradigm by enabling more efficient and accurate decision-making across the discovery and development pipeline. Advances in machine learning, deep learning, and natural language processing now support target identification, hit finding, lead optimization, and drug repurposing with unprecedented speed and precision. AI-driven insilico platforms further enhance early-stage predictability by forecasting toxicity, pharmacokinetics, and developability, thereby reducing late-stage attrition. This review critically examines the evolving role of AI in modern drug discovery and its expanding impact on pharmaceutical formulation development and personalized medicine. Collaborative models between AI developers and the pharmaceutical industries, essential for accelerating translational outcomes, are also highlighted. Finally, key challenges, including algorithmic transparency, data quality, interoperability, and regulatory acceptance, are discussed, along with future directions for harnessing AI's full potential in pharmaceutics.
References
- 1.Ali, M. S., Alqahtani, T., Shmrany, H. A., Gupta, G., Goh, K. W., Sahebkar, A., & Kesharwani, P. (2026). Artificial Intelligence in Drug Discovery and Development: Transforming Pharmaceutical Innovation. Drug Development Research. https://doi.org/10.1002/ddr.70281
Related Research
CPT: pharmacometrics & systems pharmacology
Structured Schemas for Provenance-Rich, LLM-Assisted QSP Model Calibration
2 Aug 2026
Journal of pharmacokinetics and pharmacodynamics
Diffusion models for virtual populations and pharmacometric simulations
1 Aug 2026
Journal of chemical information and modeling
HyperDC: A Non-Uniform Hypergraph Framework for Dual- and Higher-Order Drug Combination Recommendation Across Diverse Complex Diseases
29 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service